Previous systematic reviews suggest improvements in clinical outcome with oral nutritional supplements (ONS) (1) , although the role of high-protein ONS has not been widely addressed. Thus, a systematic review has been undertaken to investigate the effect of high-protein ONS v. routine care on clinical outcomes. This review has already highlighted a significant reduction in complications with high-protein ONS (2) . However, the review also aimed to investigate the effect of high-protein ONS on healthcare use, including length of stay in acute and community settings and hospital readmissions.
Previous systematic reviews suggest improvements in clinical outcome with oral nutritional supplements (ONS) (1) , although the role of high-protein ONS has not been widely addressed. Thus, a systematic review has been undertaken to investigate the effect of high-protein ONS v. routine care on clinical outcomes. This review has already highlighted a significant reduction in complications with high-protein ONS (2) . However, the review also aimed to investigate the effect of high-protein ONS on healthcare use, including length of stay in acute and community settings and hospital readmissions.
A systematic review using searches of electronic databases and bibliographies (up to January 2007) identified twenty-seven randomised controlled trials (RCT; n 2730) of multi-nutrient high-protein ONS ( ‡ 20 % total energy from protein (3) ) used in addition to diet and compared with routine care. Seven RCT (n 968) reported length of stay in hospital, including acute and community-based rehabilitation hospitals but only five RCT (n 847) had full data (mean and SD) available for analysis. Only one RCT (n 445) had data on hospital readmissions. High-protein ONS (prescribed daily intake 624-4165 kJ (149-995 kcal) energy, 18-50 g protein, 28 d-6 months) were given to patients with hip fracture (four RCT) or acutely-ill elderly patients (one RCT) in hospital or in both hospital and community settings. Meta-analysis was performed on all length-of-stay data (five RCT, n 847), and separately for acute hospital stay (three RCT) and acute and community-based rehabilitation hospital stay (two RCT) using Comprehensive Meta-Analysis version 2 (Biostat Inc., Englewood, NJ, USA). Although meta-analysis of all trials combined suggested that high-protein ONS reduced length of stay compared with routine care (-2.05 (95 % CI -3.07, -1.04) d), significant heterogeneity meant a separate analysis according to setting was more appropriate (Table) . The reduction in acute hospital length of stay with high-protein ONS was < 1 d (7% shorter than routine-care group) but there was a much greater (20 %, about 10 d) difference when community-based hospital stays were considered. The RCT that had data on hospital readmissions showed a significant reduction with high-protein ONS given in hospital and after discharge (Table) .
This systematic review and meta-analysis suggests that ONS high in protein (with ‡ 20 % total energy from protein) can significantly reduce both length of stay and hospital readmissions compared with routine care, with economic implications.
